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A mutation in the WDR4 gene, coding for a
tRNA-modifying enzyme, leads to reduced levels of
guanosine methylation in tRNA in patients with
primordial dwarfism.pathogenesisBackground
Transfer RNAs (tRNAs) have a key role in protein syn-
thesis. They act as adaptor molecules capable of reading
mRNA codons so as to deliver amino acids to the grow-
ing polypeptide in the translating ribosome. To function
properly, tRNAs need to be chemically modified post-
transcriptionally [1]. Some of the modifications help
tRNAs to maintain a distinctive tertiary structure, others
are critical for correct aminoacylation, and yet others
participate in codon reading, thus influencing efficiency
and fidelity of translation. Dysregulation of the tRNA
modification pattern, or of the levels of the enzymes that
catalyze these modifications, drastically alters tRNA
functionality and can result in complex phenotypes,
probably due to defects in protein translation [2].
Evidence is accumulating that tRNA modifications
have significant roles in human diseases [3]. However, in
many cases, although the link between tRNA modifica-
tions and pathology has been confirmed, the exact mo-
lecular mechanism behind the observed phenotypes
remains unclear. In a new study published in Genome
Biology, Shaheen and coworkers [4] describe a mutation
in the human WDR4 gene as a cause of primordial
dwarfism (PD). This gene encodes a tRNA methyltrans-
ferase and has previously been indirectly associated with
neurological disorders such as Down syndrome [5]. The* Correspondence: lluis.ribas@irbbarcelona.org
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direct evidence for the role of WDR4 in a human dis-
ease, and it addresses the molecular mechanisms behind
PD from a tRNA modification perspective.
Towards understanding tRNA modification-driven
PD is an incurable spectrum of clinical conditions
caused by various mechanisms, such as impaired DNA
damage repair or impaired mitosis due to centrosomal
abnormalities. It is characterized by growth deficiency,
brain malformation and facial dysmorphism. Although
some of the genetic causes for PD have been studied in
depth, the molecular mechanisms behind many forms
remain unknown.
WDR4 maps to human chromosome 21q22.3, a region
that has previously been associated with several genetic
disorders, such as autosomal-recessive deafness, manic-
depressive psychosis and Down syndrome [5]. Moreover,
this chromosomal region has also been investigated in
mice, where it was found that its copy number directly
affects cognition and hippocampal plasticity [6]. Further-
more, the human WDR4 gene has been found to have
two splice forms, one of which is mainly expressed in
fetal tissues, suggesting a potential role for this tran-
script in neural tissue development [5].
WDR4 encodes one of the subunits of the heterodi-
meric enzyme that is responsible for methylating carbon
7 of guanosines at position 46 (m7G46) of nine human
tRNAs. Its binding partner is METTL1, and the yeast
homologs of WDR4 and METTL1 are Trm82 and Trm8,
respectively. Lack of Trm82 or Trm8 leads to decreased
levels of m7G46 in tRNA
Phe and results in a temperature-
sensitive growth phenotype when cells are grown in syn-
thetic media containing glycerol. Importantly, in yeast,
human WDR4 and METTL1 can compensate for the lack
of Trm82 and Trm8, respectively, suggesting a conserved
role for these proteins and for the m7G46 modification in
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guineous families with members affected by a distinct
form of PD. Using autozygosity mapping and exome
sequencing they identified a homozygous mutation in
the WDR4 gene in the affected family members. More-
over, lymphoblastoid cell lines derived from these pa-
tients showed decreased levels of m7G46. To further
investigate the molecular effect of this mutation, Shaheen
and coworkers [4] created a model yeast strain bearing
the equivalent of the mutation found in human pa-
tients with PD, in the trm82 gene (Trm82-K223L). As
expected, the level of m7G46 modification was de-
creased in the Trm82-K223L mutant strain. Further-
more, the mutant yeast strain had a temperature-
sensitive growth phenotype similar to that observed
when the trm8 gene was deleted [8]. Given that Trm8
and Trm82 can catalyze guanosine methylation only if
they form a complex, the data suggested that the mu-
tation disrupts an important interaction between Trm8
and Trm82. Trm82 is the non-catalytic subunit of the
methyltransferase and serves to maintain the levels of
Trm8 by stabilizing it in an active conformation [9].
Therefore, one possibility is that the mutation in hu-
man WDR4 affects its binding to METTL1, resulting
in a reduction of m7G46 due to impaired formation of
the WDR4–METTL1 heterodimer. However, a direct
link between these observations and the severe pheno-
typic consequences observed in PD patients still needs
to be made.
The finding that a point mutation in the non-catalytic
subunit of an enzyme leads to complex phenotypes is
reminiscent of the enzyme hetADAT (heterodimeric
adenosine deaminase acting on tRNA), which deami-
nates A34 into inosine 34 (I34) in all tRNAs with the
anticodon starting with A (tRNAANN). This enzyme is
composed of two subunits, ADAT2 (the catalytic sub-
unit) and ADAT3 (a non-catalytic partner) [8]. Both
ADAT2 and ADAT3 are essential genes, although hu-
man cell lines can tolerate to some extent the reduction
in I34 levels induced by ADAT2 knockdown [9]. The
same group that now reports the WDR4 PD mutation
[4] previously reported a homozygous missense muta-
tion in ADAT3 to be associated with intellectual dis-
ability and strabismus [10]. Molecular modeling of the
part of ADAT3 containing the mutated residue showed
an altered structure of the loop where the mutated resi-
due is located [10]. Potentially, this altered conform-
ation could disturb the ADAT2–ADAT3 heterodimer
and/or tRNA binding. Mechanistically, it is possible
that the mutations in WDR4 and in ADAT3 both result
in similar consequences for heterodimer formation and
catalysis, but the effect of the lack of these modifica-
tions on the functionality of tRNA remains to be ad-
dressed in depth.Open questions and concluding remarks
The above-mentioned studies contribute to the exciting,
but still poorly explored, issue of the role of tRNA modi-
fications in human diseases. The findings of Shaheen
and coworkers [4] raise several questions. How does the
altered pattern of tRNA modifications influence the
physiological functionality of tRNAs (structure, aminoa-
cylation, tRNA recognition by the ribosome, codon de-
coding, and so on)? Does a lack of tRNA modifications
lead to overall protein translation defects or does it
affect only some particular genetic programs? Could
non-canonical functions of tRNAs be altered in these
pathological scenarios? Are there any more tRNA modi-
fications associated with other human diseases? These
and other questions are attractive research paths that de-
serve closer attention.
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